In this issue of Angiology, Kolkenbeck-Ruh et al assessed whether or not carotid intima-media thickness (cIMT) together with the presence of carotid plaque are accurate predictors of cardiovascular (CV) events in 473 patients with critical limb ischemia (CLI) or stroke compared to 479 controls. 1 The authors 1 concluded that cIMT independently complements the presence of carotid plaque in predicting noncardiac arterial events, such as stroke and CLI. Independent relations between plaque and CLI were noted in older (>50 years; P < .005 to <.0001) but not younger (P > .38) participants. Furthermore, independent relations between carotid plaque and stroke (P < .005 to <.0001) and between cIMT and CLI (P < .0001) were noted in younger participants. 1 Although the addition of cIMT to plaque presence failed to improve arterial event detection in older (>50 years) patients (area under the receiver operating curve: 0.680 + 0.020 vs 0.664 + 0.017, P ¼ .27), cIMT improved the ability to detect stroke and CLI when added to plaque in younger patients (area under the receiver operating curve: 0.719 + 0.023 vs 0.631 + 0.026, P < .0001). The conclusion reached was that cIMT complements the performance of carotid plaque presence for CV event detection in younger, but not older, patients.
In this issue of Angiology, Kolkenbeck-Ruh et al assessed whether or not carotid intima-media thickness (cIMT) together with the presence of carotid plaque are accurate predictors of cardiovascular (CV) events in 473 patients with critical limb ischemia (CLI) or stroke compared to 479 controls. 1 The authors 1 concluded that cIMT independently complements the presence of carotid plaque in predicting noncardiac arterial events, such as stroke and CLI. Independent relations between plaque and CLI were noted in older (>50 years; P < .005 to <.0001) but not younger (P > .38) participants. Furthermore, independent relations between carotid plaque and stroke (P < .005 to <.0001) and between cIMT and CLI (P < .0001) were noted in younger participants. 1 Although the addition of cIMT to plaque presence failed to improve arterial event detection in older (>50 years) patients (area under the receiver operating curve: 0.680 + 0.020 vs 0.664 + 0.017, P ¼ .27), cIMT improved the ability to detect stroke and CLI when added to plaque in younger patients (area under the receiver operating curve: 0.719 + 0.023 vs 0.631 + 0.026, P < .0001). The conclusion reached was that cIMT complements the performance of carotid plaque presence for CV event detection in younger, but not older, patients. 1 Since the development and validation of the measurement of cIMT in the 1980s, 2,3 many reports have relied on this imaging marker as a surrogate for atherosclerosis in studies of risk factors, genetics/epigenetics, and evaluation of therapies including lipid-lowering drugs. 4 It is a widespread misconception that increased cIMT represents "preclinical atherosclerosis." 5 Increased cIMT is considered by some to represent a manifestation of subclinical atherosclerosis and has therefore been included in the list of organ damage conditions in the European Hypertension Guidelines 6 and the European Prevention Guidelines. 7 However, cIMT is biologically and genetically distinct from plaque burden. 4, 5, 8, 9 Furthermore, there is confusion in the literature resulting from failure to distinguish between 2 different approaches to measuring cIMT. When measured according to the Mannheim Consensus, cIMT is measured in the far wall of the distal common carotid, at a site where there is no plaque. 10 The other main approach includes plaque thickness in the measurement of IMT, but because some patients-but not all-have plaque, combining them as if they were all the same is invalid. Plaque thickness does predict risk. 11, 12 In the Northern Manhattan Study (n ¼ 2189 participants), after a mean follow-up of 6.9 years, individuals with maximum carotid plaque thickness >1.9 mm had a 2.8-fold increased risk of combined vascular events compared to patients without carotid plaque (hazard ratio [HR]: 2.80; 95% confidence interval [CI]: 2.04-3.84). 11 In the High Risk Plaque BioImage Study (n ¼ 5808 participants; median follow-up: 2.7 years), 12 carotid plaque burden was as predictive as a coronary calcium score of future CV events (P < .001), whereas cIMT was not (P ¼ .372). Instead of measuring IMT, a better approach to assessing preclinical atherosclerosis is to measure carotid plaque burden. [12] [13] [14] [15] Carotid Total Plaque Area Carotid total plaque area (TPA) was first measured in London, Ontario, Canada, in 1986 and implemented routinely in vascular prevention clinics there in 1995. The method was described in an article on the effects on atherosclerosis of blood pressure (BP) elevation during mental stress. 16 Spence et al reported in 2002 that for 1686 patients followed up in the Premature Atherosclerosis Clinic and the Stroke Prevention Clinic of the University Campus of the London Health Sciences Center (London, Canada), the 5-year risk of stroke, myocardial infarction (MI), or vascular mortality by quartile of TPA was 5.6%, 10.7%, 13.9%, and 19.5%, after adjustment for age, sex, systolic BP, cholesterol, homocysteine, diabetes, and treatment of BP and cholesterol. 17 Measurement of plaque burden is more strongly predictive of CV events compared to measurement of cIMT. [13] [14] [15] In a study assessing the combination of risk scores with various carotid ultrasound imaging parameters (average, minimum and maximum cIMT measurements, cIMT variability, and TPA), the greatest increase in prediction of risk resulted from adding TPA to the risk score based on coronary risk factors alone, resulting in the AtheroEdge Composite Risk Score, and thereby significantly increasing the area under the curve values in receiver-operating characteristic analysis of CV risk prediction. 18 The most important studies to show that measurement of plaque burden is more strongly predictive of CV events compared to measurement of cIMT are those from Tromsø, Norway. 13, 14 The Tromsø study was a prospective, population-based study in over 6000 participants who were healthy at baseline. Both cIMT and TPA were measured by ultrasound at baseline. After a mean follow-up of 9.6 years (median: 10.8 years), a first-ever stroke occurred in 7.3% of men (n ¼ 235) and 4.8% of women (n ¼ 162). 13 After multivariate analysis for age, total cholesterol, high-density lipoprotein cholesterol, systolic BP, use of BP-lowering drugs, current smoking, prevalent diabetes, and coronary heart disease, TPA was significantly associated with ischemic stroke (HR for men: 1.23; 95% CI: 1.09-1.38; P ¼ .0009 and HR for women: 1.19; 95% CI: 1.01 -1.41; P ¼ .04). 13 The multivariable-adjusted HR in the highest quartile of TPA was 1.73 (95% CI: 1.19-2.52; P ¼ .002) in men and 1.62 (95% CI: 1.04-2.53; P ¼ .03) in women compared to individuals without plaque. 13 In contrast, cIMT was predictive of stroke only in women and only when the measurement included plaque thickness. Common carotid artery IMT in the far wall was not associated with future ischemic stroke after adjustment for other CV risk factors. 13 Similarly, TPA strongly predicted coronary risk after 7 years of follow-up, whereas only cIMT in the bulb was predictive. 19 A subsequent meta-analysis verified that IMT including plaque thickness in the bulb was a strong predictor of CV events (detection of coronary artery disease and future MI) than was IMT in the common carotid artery where the prevalence of plaque is lower than in the bulb and that measurement of carotid plaque burden was more predictive than either IMT phenotype. 15 Again, this means that adding plaque thickness to IMT makes it more predictive of events, but it combines patients with and without plaque as if they were the same.
A common error (noted in the study by Kolkenbeck-Ruh et al 1 and others 20 ) is the comparison of the presence or absence of carotid plaque (a categorical variable) with the quantity of IMT as a continuous variable. Continuous variables are about 3 times more powerful for statistical purposes than categorical variables. 16 Compared to cIMT, measurement of carotid plaque volume by 3-dimensional (3D) ultrasound reduces the sample size and duration of treatment needed to evaluate new therapies by 2 orders of magnitude. 16 Unlike cIMT, carotid plaque burden measured by 3D ultrasound is highly correlated with coronary calcium scores 21 and predictive of risk of major adverse cardiac events (CV death, MI, and stroke). 22 The High Risk Plaque BioImage Study compared cIMT, carotid plaque burden, and maximum carotid plaque thickness in nearly 6000 individuals. 21 Both carotid plaque burden and carotid plaque thickness were predictive of primary and secondary major CV events, whereas cIMT was not. 21 Furthermore, progression of plaque area 17 and total plaque volume 23 significantly predict risk, whereas progression of cIMT does not. 24 A major advantage of measuring carotid plaque burden is that progression/regression of plaque can be measured in clinically relevant time frames. The spatial resolution of carotid ultrasound is *0.3 mm, and on average, cIMT changes by only 0.15 mm/year. 25 It is therefore not possible to reliably measure change in cIMT within an individual over a year; this is why the consensus sample size for studies of effects of therapy on IMT is 200 to 300 patients per group, followed for 2 years. 26 Because in coronary intravascular ultrasound studies plaque is present throughout the length of the pullback, change in coronary plaque burden reduces to a single dimension (the average thickness). 16 Therefore, sample sizes and duration of follow-up for studies of effects of therapy on coronary plaque are also *200 patients per group followed for 2 years. 27 However, because carotid plaques are focal, they can change in 3 dimensions: thickness, length, and circumferential extent. 16 Carotid plaques grow in the axis of flow, and plaque length changes 2.4 times faster than thickness. 16 Plaque volume and area change within 3 months, 28,29 so they are very effective measures to assess and guide preventive therapy. This led to a new approach to vascular prevention, "treating arteries instead of treating risk factors." 30 Implemented in 2003, it was associated with a >80% reduction in the 2-year risk of stroke and MI among high-risk patients with asymptomatic carotid stenosis. 31 "Treating atherosclerosis without measuring plaque would be like treating hypertension without measuring BP." 30 It is a great mystery why investigators continue to measure cIMT for risk prediction. It is no longer recommended in the 2013 American College of Cardiology/American Heart Association Guidelines or the 2016 European Guidelines on CV disease prevention in clinical practice. 32, 33 The recently published 2019 European Society of Cardiology/European Atherosclerosis Society Guidelines for the management of dyslipidemias clearly mention that measurement of cIMT is inferior to coronary artery calcium score/carotid plaque detection and support assessment of carotid or femoral plaque burden with ultrasound to be predictive of CV events. 34 In patients with no plaque, a better alternative to cIMT (and to coronary calcium) 29 is measurement of 3D vessel wall volume. 35, 36 There is a need to shift to the more advanced 3D technologies that are becoming available, not only for better and more accurate CV risk prediction but also to better monitor and quantify the effects of therapy to treat atherosclerosis. 12 Automated methods will be coming soon and will make this feasible in any laboratory with modern ultrasound equipment. 37 
